Randomized trial reveals high clinical success across four pulp capping agents in dental patients, suggesting growth factor therapy and Biodentine offer viable alternatives to calcium hydroxide.
Background: Preserving pulp vitality is crucial for maintaining tooth function and structure. Vital pulp therapy uses pulp capping agents to promote pulp healing and regeneration. Aims: This study evaluated the outcomes of four different pulp capping agents. Materials and Methods: One hundred and twenty patients were randomly assigned to four groups: G1 – calcium hydroxide (CH), G2 – growth factor (Recombinant human Platelet-Derived Growth Factor-BB + Beta-Tricalcium Phosphate (rh-PDGF-bb+ βTCP)), G3 – Biodentine, and G4 – Cissus quadrangularis (CQ). After caries removal, the agents were applied to the exposed pulp, sealed with glass ionomer cement, and restored with composite. Clinical and radiographic follow-ups were conducted at 1, 6, and 12 months, and the data were statistically analyzed. Results: The highest success rate was observed in the growth factor group (96.7%), followed by Biodentine (93.3%), CQ (90%), and CH (80%). However, the differences among groups were not statistically significant ( P > 0.05). Dentin bridge formation was the most frequent in the growth factor group (76.67%), and treatment failures were more common in patients over 40 years. Conclusion: Growth factor (rh-PDGF-bb + βTCP) demonstrated the highest success rate, positioning it as a superior alternative to CH. CQ also showed potential as an effective pulp capping agent, warranting further investigation.
No takes yet. Share an insight, caveat, or question.
Yadav et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: